Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ayala Pharmaceuticals Inc
(OP:
ADXS
)
0.0200
-0.0005 (-2.44%)
Streaming Delayed Price
Updated: 12:55 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ayala Pharmaceuticals Inc
< Previous
1
2
3
Next >
Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
May 09, 2024
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
March 26, 2024
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
February 20, 2024
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
February 06, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
February 06, 2024
AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
November 06, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
October 23, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
October 19, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 10, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
August 01, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
July 27, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
July 05, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
June 05, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 30, 2023
May 30, 2023
Via
Benzinga
Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 23, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2023
Poster will feature updated results from Phase 2 portion of RINGSIDE, evaluating AL102 in desmoid tumors
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Inc. (OTC:ADXS) Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors
March 08, 2023
Ayala Pharmaceuticals Inc. (OTC:ADXS) Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors
Via
News Direct
Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee
March 03, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022
February 10, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals and Advaxis Agree To Combine, Expect Uplisting On NASDAQ
October 19, 2022
Ayala Pharmaceuticals Inc (NASDAQ: AYLA) and Advaxis Inc (OTC: ADXS) have announced a merger agreement.
Via
Benzinga
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
October 19, 2022
From
Ayala Pharmaceuticals
Via
GlobeNewswire
ADXS Investor Alert – Monteverde & Associates PC and Kahn Swick & Foti, LLC Obtain Material Disclosures Regarding the Upcoming Shareholder Vote for Advaxis, Inc. - ADXS
March 28, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
December 22, 2021
Gainers BioCardia (NASDAQ:BCDA) shares ro...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
December 10, 2021
Gainers Reshape Lifesciences (NASDAQ:RSLS...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
November 30, 2021
Gainers Lannett (NYSE:LCI) shares rose 11.61...
Via
Benzinga
6 of the Hottest Stocks to Pick Up for Less Than $1
November 01, 2021
These penny stocks are trading for under a dollar, but could change that in the coming months with their strong fundamentals.
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
September 30, 2021
Gainers FibroGen (NASDAQ:FGEN) stock mov...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
September 16, 2021
Gainers Stealth BioTherapeutics (NASDAQ:
Via
Benzinga
72 Biggest Movers From Yesterday
September 14, 2021
Gainers aTyr Pharma, Inc. (NASDAQ: LIFE) jumped 67% to settle at $9.15 on Monday as the company announced positive results from its Phase 1b/2a trial evaluating its lead...
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.